ADMA Biologics (NASDAQ:ADMA) Stock Price Up 8.8% – Should You Buy?

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) rose 8.8% during mid-day trading on Monday . The company traded as high as $21.18 and last traded at $21.11. Approximately 4,282,141 shares traded hands during trading, an increase of 20% from the average daily volume of 3,567,260 shares. The stock had previously closed at $19.40.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Up 7.8 %

The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm’s 50-day moving average price is $17.78 and its 200 day moving average price is $18.15. The firm has a market capitalization of $4.94 billion, a price-to-earnings ratio of 74.68 and a beta of 0.53.

Institutional Investors Weigh In On ADMA Biologics

Large investors have recently bought and sold shares of the stock. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics in the 3rd quarter worth approximately $61,858,000. Raymond James Financial Inc. acquired a new position in ADMA Biologics in the fourth quarter valued at $19,076,000. EWG Elevate Inc. purchased a new position in ADMA Biologics during the fourth quarter worth about $480,000. Allspring Global Investments Holdings LLC boosted its stake in ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after buying an additional 2,613,482 shares during the last quarter. Finally, Veracity Capital LLC grew its holdings in ADMA Biologics by 117.0% in the 4th quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company’s stock valued at $796,000 after buying an additional 25,030 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.